SAR317461 抑制JAK2/STAT3酸化以增强抗白血病活性
Xiao-Yu Yang1, Yan Wang1, Lin Zhang1
1Department of Hematology, The Fifth Affiliated Hospital of Zhengzhou University, No.3 Kangfuqian Street, Zhengzhou, 450000 China.
概括
SAR317461,一种新的Janus激酶 (JAK) /信号转换器和转录激活器 (STAT) 抑制剂,通过抑制细胞生长和诱导亡,有效向急性髓性白血病 (AML). 这种有前途的疗法在临床前模型中显示出有效性,并具有良好的安全性.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 由于高死亡率,急性髓性白血病 (AML) 具有重大治疗挑战.
- 简氏激酶 (JAK) /信号转换器和转录激活器 (STAT) 途径与AML病变有关.
- 针对JAK/STAT途径提供了一个有前途的AML治疗策略.
研究的目的:
- 在AML的临床前模型中研究SAR317461,一种新型JAK/STAT抑制剂的疗效.
- 阐明SAR317461在AML细胞中的作用机制.
- 评估SAR317461. 的体内疗效,药理动力学和安全性.
主要方法:
- 在体外测试中评估了SAR317461对AML细胞活力,亡和自的作用.
- 西部斑点分析证实了JAK/STAT通路的抑制.
- 在体内研究中使用AML小鼠模型来评估疗效,药理动力学和生物安全性.
主要成果:
- SAR317461证明了剂量依赖的AML细胞增殖和诱导的亡的抑制.
- 该抑制剂降低了JAK2和STAT3酸化的调节,并刺激了自.
- 在体内,SAR317461降低了白细胞形成,在AML小鼠中延长了生存时间,并表现出良好的药理动力学,没有显著的毒性.
结论:
- 通过向JAK/STAT通路,SAR317461在体外和体内有效地抑制AML的进展.
- 该化合物诱导了亡和自,这是其抗白血病活性的关键机制.
- SAR317461显示出作为AML新型向治疗的潜力,需要进一步的临床研究.
相关概念视频
01:20The JAK-STAT Signaling Pathway
13.3K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
13.3K
01:22PI3K/mTOR/AKT Signaling Pathway
5.8K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
5.8K
03:03mTOR Signaling and Cancer Progression
4.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.9K
02:34Inhibition of Cdk Activity
6.1K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
02:23Abnormal Proliferation
5.3K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.3K
02:50Combination Therapies and Personalized Medicine
6.2K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K